Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.

Seven Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in first complete remission received maintenance therapy with imatinib alone. Two-year progression-free survival was 75%. Quantitative polymerase-chain-reaction (qPCR) monitoring of BCR-ABL showed that: (i) persisting molecular complete response (CR) was associated with long-lasting CR; (ii) molecular relapse did not invariably mean hematologic relapse; (iii) only the wide and rapid increment of BCR-ABL values was predictive of leukemia relapse.
AuthorsLeonardo Potenza, Mario Luppi, Giovanni Riva, Roberto Marasca, Silvia Martinelli, Giuseppe Torelli
JournalHaematologica (Haematologica) Vol. 90 Issue 9 Pg. 1275-7 (Sep 2005) ISSN: 1592-8721 [Electronic] Italy
PMID16154854 (Publication Type: Comparative Study, Letter)
Chemical References
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Adult
  • Aged
  • Benzamides
  • Disease-Free Survival
  • Female
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy, pathology)
  • Male
  • Middle Aged
  • Piperazines (therapeutic use)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, pathology)
  • Pyrimidines (therapeutic use)
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: